Pharmaceutical Makers Ceva, Sogeval Ponder Merger
Ceva Santé Animale, one of Europe’s largest veterinary drug companies, reported today that it is negotiating a merger with French competitor Sogeval.
Ceva and Sogeval combined for nearly $900 million in sales in 2012.
Ceva produces pharmaceuticals and vaccines for companion animals, cattle, pigs and poultry. Among its products for cats and dogs are Vectra anti-parasitics and Feliway and Adaptil pheromone-based behavior items.
Sogeval, a subsidiary of agri-food giant Sofiprotéol, offers a range of products for pets and livestock. Its catalog includes medicated shampoos and sprays, Derma-3 nutritional supplements, Chondro-Flex joint care formulas, and Clenz-a-dent dental chews and fluoride foam.
A merger would give the combined company a greater foothold on the world veterinary market.
"The decision behind this project was made with both our hearts and minds,” said Marc Prikazsky, president and CEO of Ceva, which is based in Libourne, France. "We share the same business philosophy, one which will allow us to grow faster together.”
Ceva is by far the larger of the two companies, with global revenue of $782 million in 2012 and more than 3,000 employees. Ceva’s North American headquarters are in Lenexa, Kan.
Sogeval, based in Laval, France, recorded 2012 sales of more than $100 million and employs 290 people. The company opened a North American subsidiary, Sogeval Laboratories Inc., in Irving, Texas, in 2006.
"For Sogeval, this alliance would create the opportunity to accelerate our development by rolling out our expertise globally,” said CEO José Daoudal.
Sogeval expanded in early 2013 with the takeover of British veterinary products manufacturer Alstoe Ltd., now Sogeval UK Ltd.